Status:
TERMINATED
Safety and Tolerability of Lu AG06479 in Healthy Young Men
Lead Sponsor:
H. Lundbeck A/S
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the safety and tolerability of Lu AG06479 and what the body does to Lu AG06479 after swallowing single doses of the drug.
Detailed Description
Part A: randomized, sequential Part B: open-label, cross-over
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy, young, non-smoking men, weight ≥60 kg, and a body mass index (BMI) ≥18.5 kg/m2 and ≤30 kg/m2 at the Screening Visit.
- Other in- and exclusion criteria may apply
Exclusion
Key Trial Info
Start Date :
July 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 10 2021
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT04473651
Start Date
July 9 2020
End Date
November 10 2021
Last Update
December 14 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Covance
Madison, Wisconsin, United States, 53704